Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Actinogen — Investor Presentation (March 2014)
17 slides from Actinogen Medical's investor presentation, Mar 18, 2014
Slide 1: Actinogen Ltd - A Diversified Biotechnology Company
For personal use only Actinogen Ltd (ASX: ACW) A Diversified Biotechnology Company
Slide 2: Disclosures
Disclosures For personal use only This presentation has been prepared by Actinogen Limited (or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to m
Slide 3: Capital Structure
Capital Structure For personal use only Ord Shares on Issue 201.1M Options ($0.02 exercise, 50M 30/11/18) Options ($0.4 exercise, 9.1M 30/09/15) Share Price (14/3/14) $0.03 Market Cap $6.03M Cash $1.353M Enterprise Value $4.68M Top 20 Shareholders 71%
Slide 4: Experienced Management and Board
Experienced Management and Board For personal use only Dr Brendan de Kauwe, Executive Director Dr de Kauwe studied a Bachelor of Science and Bachelor of Dental Surgery at the University of Western Australia, and also holds a Graduate Diploma in Applied Finance (Corporate Finance). Dr de Kauwe’s ex
Slide 5: 2013 - 2014 Highlights
2013 - 2014 Highlights For personal use only 1. Actinogen Signed an Agreement with Curtin University 2. Actinogen Recommenced to Conduct Further Research in Trials in Antibiotic Project Cancer Stem Cells Project 3. Laboratory Moved to State 4. Established New Collaboration Agricultural Biotechnology
Slide 6: Ongoing Partnerships
Ongoing Partnerships For personal use only Pioneering research work to identify new agents targeting Cancer Stem Cells using methods and techniques established at Curtin University laboratories Ongoing research activities by Actinogen’s scientists in the areas of cancer stem cells antibiotics, and b
Slide 7: Research Programs
For personal use only Research Programs
Slide 8: Cancer Stem Cells
Cancer Stem Cells Program For personal use only The program is focused on discovering and developing drugs to treat brain cancer as well as having the potential to address other oncological diseases, through the targeted killing of cancer stem cells (CSCs). What Are Cancer Stem Cells? Cancer stem
Slide 9: Cancer Stem Cells first results
Cancer Stem Cells Program For personal use only first results… Treatment with carboplatin enriched Addition of isolate 5059 to carboplatin kills CD133+ population (bottom plot, green most of the CD133+ cells (bottom plot, population in R3 area) green population in R3 area) Next step: Actinogen
Slide 10: Antibiotics - Three Areas of Interest
Antibiotics Program For personal use only Currently Three Areas of Interest A: MRSA: antibiotic resistant golden Staphylococci B: Anti - Clostridium difficile C: Anti - Candida agents Large market opportunity in treating bacterial infections resistant to common antibiotics (see diagram) Source
Slide 11: Antibiotics - MRSA
Antibiotics Program For personal use only (A) methicillin-resistant Staphylococcus aureus (MRSA) Actinogen currently has 19 actinomycetes that are producing antibiotic molecules that are different from all antibiotics screened for via Actinogen’s internal de-replication libraries. These active mol
Slide 12: Antibiotics - Clostridium Difficile and Anti Candida
Antibiotics Program For personal use only (B) Clostridium Difficile This is an anaerobic bacterium that is relatively new in the collective known as “emerging” pathogens. This bacteria lives in the gastrointestinal tract. Current antibiotics used in its treatment also kill normal gut flora leading
Slide 13: Bioethanol Project Overview
Bioethanol Program For personal use only Project Overview ACW signed a coloration agreement with Leaf Energy Ltd on 23 December 2013 to fully fund further trials in ACW’s bioethanol project ACW has identified Actinomycetes strains that produce Cellulases and Lignases as a by- product. These Enzy
Slide 14: Bioethanol - Initial Results are Very Positive
Bioethanol Program For personal use only Initial Results are Very Positive Commercial cellulases were titrated against an actinomyceteACN4205; 4205 showed better activity Actinogen’s results were confirmed and cultural conditions optimised using larger fermentation vessels up to 10 litres in res
Slide 15: Bioethanol - Large Market Opportunity
Bioethanol Program For personal use only Large Market Opportunity LER plans to licence the discovered IP from ACW for the exclusive use in its innovative and patent protected Glycerol Pretreatment Process for the production of biofuels ACW will receive a royalty payment on net profits from LER o
Slide 16: Actinogen is Looking for Partnership Opportunities
Other Program For personal use only Actinogen is Looking for Partnership Opportunities Shikimic Acid Project Salt Tolerance Project Plant Growth Hormone Project Biofumigation Project
Slide 17: Contact Us
Contact Us: For personal use only Actinogen – A Diversified Biotechnology Company Principal / Registered Office Level 2, 1 Walker Avenue West Perth WA 6005 Postal Address PO Box 271 West Perth WA 6872 Contact Details Telephone: 08 9481 3860 Facsimile: 08 9321 1204 www.actinogen.com.au ABN 1408677847